ATyr (LIFE) Surges On Collaboration Deal With Kyorin Pharma
Zacks Investment Research | Jan 06, 2020 09:19PM ET
Shares of aTyr Pharma, Inc. (NASDAQ:LIFE) surged more than 43% after it announced a collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Kyorin Holdings, Inc.
Both companies have entered into a collaboration for the development and commercialization of aTyr’s lead candidate, ATYR1923, for interstitial lung diseases (ILDs) in Japan.
Per the agreement, aTyr will receive an $8-million upfront payment and is eligible to receive up to an additional $167 million in milestone payments as well as tiered royalties on net sales in Japan. Kyorin, a leading respiratory focused pharmaceutical company in Japan, will receive the exclusive right to develop and commercialize ATYR1923 in Japan for ILDs and will be responsible for funding all research, development, regulatory, marketing and commercialization activities. Meanwhile, aTyr will supply all drug products for Japan and support development activities as the global development leader for ATYR1923.
ATYR1923 is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states. aTyr is currently enrolling in a proof-of-concept phase Ib/IIa study evaluating ATYR1923 in patients with pulmonary sarcoidosis. This is a multi-ascending dose, placebo-controlled, first-in-patient study that has been designed to evaluate the safety, tolerability, steroid-sparing effect, immunogenicity and pharmacokinetics profile of multiple doses of ATYR1923.
Investors are optimistic about this collaboration deal.
Shares of the company have rallied 28.3% in the past six months compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.